McGuire Capital Advisors’s Acurx Pharmaceuticals ACXP Stock Holding History

McGuire Capital Advisors’s Portfolio ACXP Stock Details ACXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,000	Closed	-$3.71K	–	910
2026 Q1	$3.71K	Buy	+1,000	New	+$2.84K	﹤0.01%	569

Other funds holding ACXP

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

PFS

Prospect Financial Services Melville, New York $197M AUM 24.49% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

IWC

Integrated Wealth Concepts Waltham, Massachusetts $20.5B AUM 24.45% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

WIM

Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

McGuire Capital Advisors's ACXP Position: Q2 2026 in Review

McGuire Capital Advisors sold out of Acurx Pharmaceuticals (ACXP) in Q2 2026, closing a stake of 1,000 shares — an estimated $3.71K sold.

McGuire Capital Advisors first reported a position in ACXP in Q1 2026 and held it in 1 quarter. The position peaked at $3.71K in Q1 2026. 19 funds tracked by Wall St. Rank hold ACXP as of Q2 2026.

McGuire Capital Advisors reported no remaining Acurx Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
McGuire Capital Advisors sold 1,000 Acurx Pharmaceuticals shares in Q2 2026, an estimated $3.71K.
McGuire Capital Advisors first reported a position in Acurx Pharmaceuticals in Q1 2026 and held it in 1 quarter.
McGuire Capital Advisors's Acurx Pharmaceuticals position peaked at $3.71K in Q1 2026.
19 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q2 2026.

Based on McGuire Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.